BioNTech Results Presentation Deck

Highlights in Q2: Corporate & Oncology Pipeline 8 Corporate Updates Oncology: Pipeline Advancement ● ● ● Reported Q2 total revenues of €3.2 bn¹ and year-to-date revenues of €9.6 bn¹ Began construction of first BioN Tainer mRNA vaccine manufacturing facility in Africal Signed new equal share cost/profit collaboration agreement with Genmab for joint development of an antibody targeting CD27 BNT122 (iNeST): Positive data from Phase 1 trial in patients with resected pancreatic cancer showing favorable safety profile and encouraging signs of clinical activity² BNT116 (Fix Vac): FPD in Phase 1 trial in advanced NSCLC BNT142 (RiboMab): FPD in Phase 1/2 trial in CLDN6 positive solid tumors. BNT211 (CLDN6 CAR-T cell therapy): EMA Priority Medicines (PRIME) designation for 3rd or later-line treatment of testicular cancer 1 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021 as well as the Quarterly Report as of and for the three and six months ended June 30, 2022, filed as an exhibit to BioNTech's Current Report on Form 6-K filed on August 8,2022. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively. 2 Investigator-initiated trial BIONTECH

View entire presentation